Stock Research for LLY

Featured Broker: Ally Invest

Get the due diligence for another stock.


LLY Stock Chart & Research Data

The LLY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the LLY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


LLY Due diligence Resources & Stock Charts

The LLY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View LLY Detailed Price Forecast - CNN Money CNN View LLY Detailed Summary - Google Finance
Yahoo View LLY Detailed Summary - Yahoo! Finance Zacks View LLY Stock Research & Analysis -

Stock Analysis

TradeIdeas View LLY Trends & Analysis - Trade-Ideas Barrons View LLY Major Holders - Barrons
NASDAQ View LLY Call Transcripts - NASDAQ Seeking View LLY Breaking News & Analysis - Seeking Alpha
Spotlight View LLY Annual Report - OTC Report View LLY OTC Short Report -
TradeKing View LLY Fundamentals - TradeKing Charts View LLY SEC Filings - Bar Chart
WSJ View Historical Prices for LLY - The WSJ Morningstar View Performance/Total Return for LLY - Morningstar
MarketWatch View the Analyst Estimates for LLY - MarketWatch CNBC View the Earnings History for LLY - CNBC
StockMarketWatch View the LLY Earnings - StockMarketWatch MacroAxis View LLY Buy or Sell Recommendations - MacroAxis
Bullish View the LLY Bullish Patterns - American Bulls Short Pains View LLY Short Pain Metrics -

Social Media Mentions

StockTwits View LLY Stock Mentions - StockTwits PennyStocks View LLY Stock Mentions - PennyStockTweets
Twitter View LLY Stock Mentions - Twitter Invest Hub View LLY Investment Forum News - Investor Hub
Yahoo View LLY Stock Mentions - Yahoo! Message Board Seeking Alpha View LLY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for LLY - Insider Cow View Insider Transactions for LLY - Insider Cow
CNBC View LLY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for LLY - OTC Markets
Yahoo View Insider Transactions for LLY - Yahoo! Finance NASDAQ View Institutional Holdings for LLY - NASDAQ

Stock Charts

FinViz View LLY Stock Insight & Charts - StockCharts View LLY Investment Charts -
BarChart View LLY Stock Overview & Charts - BarChart Trading View View LLY User Generated Charts - Trading View

Latest Financial News for LLY

Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes
Posted on Tuesday August 14, 2018

Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.

Analyzing Nektar Therapeutics’ Financial Performance
Posted on Tuesday August 14, 2018

Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017. 

Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
Posted on Tuesday August 14, 2018

In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.

Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
Posted on Tuesday August 14, 2018

In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.